CMIC HOLDINGS Co., Ltd.

CMIC Group pioneered the CRO business in Japan over 28 years ago. Since then CMIC has continued as a leading innovator in the industry and has expanded services to encompass the entire pharmaceutical value-chain. We pride ourselves on meeting customers where they are and with exactly what they need to move their products forward. CMIC offers tailored solutions for pharmaceutical companies, medical device manufacturers, academia, bio-ventures and medical institutions. Using our collective strengths, we offer a broad range of services from preclinical research to practical applications with over 7,000 employees.

Cold Spring Biotech Corp.

Cold Spring Biotech (CSB) Corp is a professional agent for the world-renowned brands of cutting-edge precision medical instruments and has established excellent reputation and popularity worldwide. We have perfect sales links for selling precision instruments and reagents in the Greater China region for more than 30 years with several business offices branched in Taipei, Taichung, Tainan, Beijing, Shanghai, Guangzhou and Hong Kong covering the region.
Our cutting-edge testing and research technology center for precision medicine was established and located in Taipei. The laboratory is missioned to develop our own innovative technology platform, LDTs and IVD products, and provides technical services, total solutions and project cooperation to our clients.

List of products and services:
1. System solutions for precision testing, gene medicine and cell therapy.
2. CSB's products and services: cancer-related molecules (EGFR, BRAF gene mutations), spinal muscular atrophy (SMN1/2 gene quantification), virus testing development (COVID-19, HBV).
3.Multiple gene expression detection service (NanoString, NCOUNTER FLEX): FFPE RNA extraction service, original reagents on-board service.
4.Trace protein detection service (Quanterix, Simoa HD-1): original reagents valet on-board service, customized reagent development.
5.Cell-related technical services (Fluxion, IsoFlux): circulating tumor cell (CTC) enrichment, CTC counting.

CSL Behring

In 2001, the Executive Yuan approved the National Blood for National Health Policy to promote the use of blood from blood donation and blood preparation by commissioned manufacturers. The goal is to be self-sufficient and provide the nationals with safe blood preparation for medical use in order to ensure the health of the nationals. According to the National Blood for National Health Policy, the “national blood” is defined as the blood from blood donation by the nationals and the blood preparation thereof. To improve safety and quality of blood preparation and ensure its stable supply, the Plasma Derivatives Act was formulated to authorize the central competent authority to develop the Blood Preparation Development Program to promote relevant development measures to ensure stable supply of blood preparation in the country.
To be in line with the national policy, TBSF screened plasma raw materials that were voluntarily donated from eligible nationals. After the raw materials passed virus mark test and highly sensitive nucleic acid amplification testing (NAT), they were entrusted to the Australian-based PIC/S GMP CSL Behring plasma factory, which has been approved by the Food and Drug Administration, Ministry of Health and Welfare for manufacturing four products: ““TBSF” (20%) Human Albumin Solution, “TBSF” Human Immunoglobulin for Intravenous Use, “TBSF” High Purity Factor VIII / Von Willebrand Factor Concentrate, and“TBSF” High Purity Factor IX Concentrate.
From national plasma raw materials to final “TBSF” blood products, the whole process is checked by the Therapeutic Goods Administration (TGA) in Australia and the Food and Drug Administration, Ministry of Health and Welfare (TFDA) to ensure the quality and safety, from plasma raw materials screening to final blood preparation, is in line with international standards so that the rights and interests of domestic patients are ensured.

Delta Electronics, Inc

Dagene G1 Automated Nucleic Acid Analysis System, comprising an automated nucleic acid analyzer and a patented compatible cassette, provides a one stop processing from “nucleic acid extraction” through real-time PCR to “analysis report generation”. Our automated system is equipped with interactive UI guidance, which is easy to use and adapt. General medical staff can learn to operate our system with a minimal training. Dagene G1 Automated Nucleic Acid Analysis System can achieve the ultimately goal of effective disease prevention and control worldwide.

Development Center for Biotechnology

Biologics
Pharmaceutics
Pharmacology & Drug Disposition
Cell therapy
https://www.dcb.org.tw/posts/850

Double Eagle Enterprise Co., Ltd.

centrifuge LN2 storage system COMPUTER CONTROLLED FREEZERS
Laboratory Refrigerator/freezer(4℃/-30℃)
deep freezer

DuoGenic StemCells corporation

Founded in 2018, DuoGenic StemCells Corp. was formed by a team of passionate researchers focused on stem cell cultivation. The company aims to push its products as the future standard for stem cell culture by providing high-quality and certified stem cell culture media that can be used for both 2D and 3D cultures. The company factory is ISO13485 certified and GMP-grade. Products were controlled through rigorous quality procedures. Currently, we have two stem cells culture media on the market. AllPhase human MSC culture medium is a xeno-free medium supporting the growth and expansion of human mesenchymal stem cells, including bone marrow mesenchymal stem cell adipose-derived stem cell and umbilical cord-derived mesenchymal stem cell without the need of coating procedures. Our other product. Pluto human iPS/ES cell culture medium, is a chemically defined, serum-free, xeno-free medium designed to support the growth and expansion of human-induced pluripotency stem cell (iPSC) and embryonic stem cell (ESC) in a feeder-free culture system. Pluto medium maintains pluripotent cells without containing high levels of bFGF and other growth factors or cytokines. Furthermore, we have developed a new cell isolation technique, Peripheral Cell Purification (PCP), that can effectively isolate monocytes from peripheral blood. These monocytes possess the function to secrete growth factors, anti-inflammatory factors, and collagen, which can be used as a cell therapy option in treating Osteoarthritis.

EirGenix, Inc.

EirGenix believes that health should be advocated for all people. As one of Taiwan’s top biopharmaceutical companies, EirGenix continues to unwaveringly stand by this principle as it provides services aiding clients in creating biosimilars and new drugs, along with manufacturing its own biologics that improve and save lives. With Taiwan’s best in its team, EirGenix offers a customer-focused and transparent experience through its contract development and manufacturing operations (CDMO) unit, where it collaborates with clients to actualise their biologics. Alongside its CDMO unit, the company applies its industry expertise in developing in-house products through its product development and operations unit. Other products and services offered by EirGenix include cell line development, antibody drug conjugates, cGMP-approved production for microbial and mammalian systems, Covid-19 rapid antigen tests, and more. The company continues to develop medical marvels such as carrier proteins for vaccinations and antibody products that treat late-stage cancer. We strive to be a highly reliable source for our clients, but what's most important is to consider the health of the whole world, says Dr Liu-Lee-cheng, founder, president and CEO. EirGenix is a fast-growing biopharmaceutical company. We aim to lead Asia's biopharmaceutical manufacturing and development industries, but beyond that, I envision EirGenix becoming an international biopharmaceutical leader. Demonstrating its tenacity to go global, EirGenix was certified in 2017 by the Ministry of Health, Labour and Welfare of Japan as a foreign manufacturer of biologics, and its facility was approved by Japan’s Pharmaceutical and Medical Device Agency in 2020. The company is now applying for a Biologic License Application from the US FDA. EirGenix is open to CDMO collaborations and joint ventures with industry leaders. It is also keen to connect with investors, mergers and research and development facilities as it builds its biotechnology infrastructure to provide unrivalled patient services worldwide.

ESCO LIFESCIENCES TAIWAN CO., LTD.

Ultra Low Temperature, Biosafety Cabinet, Co2 Incubator, Centrifuge, Cell Processing Isolator, Bioreactor

Ever Supreme Bio Technology Co.,Ltd.

Ever Supreme Biotechnology Co., LTD.
New Drug Development：
Focus on immune cell therapies (CAR-T、ADCV、DC-CIK、CIK、GDT)treating cancers and umbilical mesenchymal stem cell treating myocardial infarction, stroke, COVID-19 and other major diseases.
Cell Therapy CMO：
Ever Supreme offers the cell products (DC、DC-CIK、CIK、GDT、BMSC and ADSC) needed by medical institution under the Regulations Governing Specific Cellular Therapeutic Technology of 2018 promogulated by Taiwan FDA.